[
  {
    "sentence": "Cumulative rates of ICH continued to increase during anticoagulation in patients with brain cancer (from 0.33% at 10 days to 3.16% at 90 days from the index VTE), whereas the increase was less pronounced in patients with nonbrain cancer or without cancer (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "At completing the risk analysis, brain cancer was the strongest predictor of ICH (subdistribution HR, 13.9; 95% CI, 8.05-24.1) compared with nonbrain cancer (subdistribution HR, 1.60; 95% CI, 1.15-2.21) and without cancer (reference) (Table 4 and Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, in patients with active brain cancer, death due to bleeding continued to increase during follow-up, whereas rates of death due to VTE (fatal PE) were higher in the early phases after VTE diagnosis and then reached a plateau (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "At completing the multivariable risk analysis, patients with brain cancer and nonbrain cancer had a higher risk of recurrent VTE (subdistribution HR, 3.23; 95% CI, 2.13-4.86 and subdistribution HR, 2.97; 95% CI, 2.64-3.34, respectively) than patients without cancer (Table 4 and Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Rates of ICH, fatal ICH, and recurrent VTE were numerically (not significantly) higher in patients with glioblastoma than those with other malignant brain tumors (Table 5 and Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cumulative rates of ICH continued to increase during anticoagulation in patients with brain cancer (from 0.33% at 10 days to 3.16% at 90 days from the index VTE), whereas the increase was less pronounced in patients with nonbrain cancer or without cancer (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "At completing the risk analysis, brain cancer was the strongest predictor of ICH (subdistribution HR, 13.9; 95% CI, 8.05-24.1) compared with nonbrain cancer (subdistribution HR, 1.60; 95% CI, 1.15-2.21) and without cancer (reference) (Table 4 and Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, in patients with active brain cancer, death due to bleeding continued to increase during follow-up, whereas rates of death due to VTE (fatal PE) were higher in the early phases after VTE diagnosis and then reached a plateau (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "At completing the multivariable risk analysis, patients with brain cancer and nonbrain cancer had a higher risk of recurrent VTE (subdistribution HR, 3.23; 95% CI, 2.13-4.86 and subdistribution HR, 2.97; 95% CI, 2.64-3.34, respectively) than patients without cancer (Table 4 and Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Rates of ICH, fatal ICH, and recurrent VTE were numerically (not significantly) higher in patients with glioblastoma than those with other malignant brain tumors (Table 5 and Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cumulative rates of ICH continued to increase during anticoagulation in patients with brain cancer (from 0.33% at 10 days to 3.16% at 90 days from the index VTE), whereas the increase was less pronounced in patients with nonbrain cancer or without cancer (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "At completing the risk analysis, brain cancer was the strongest predictor of ICH (subdistribution HR, 13.9; 95% CI, 8.05-24.1) compared with nonbrain cancer (subdistribution HR, 1.60; 95% CI, 1.15-2.21) and without cancer (reference) (Table 4 and Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, in patients with active brain cancer, death due to bleeding continued to increase during follow-up, whereas rates of death due to VTE (fatal PE) were higher in the early phases after VTE diagnosis and then reached a plateau (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "At completing the multivariable risk analysis, patients with brain cancer and nonbrain cancer had a higher risk of recurrent VTE (subdistribution HR, 3.23; 95% CI, 2.13-4.86 and subdistribution HR, 2.97; 95% CI, 2.64-3.34, respectively) than patients without cancer (Table 4 and Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Rates of ICH, fatal ICH, and recurrent VTE were numerically (not significantly) higher in patients with glioblastoma than those with other malignant brain tumors (Table 5 and Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cumulative rates of ICH continued to increase during anticoagulation in patients with brain cancer (from 0.33% at 10 days to 3.16% at 90 days from the index VTE), whereas the increase was less pronounced in patients with nonbrain cancer or without cancer (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "At completing the risk analysis, brain cancer was the strongest predictor of ICH (subdistribution HR, 13.9; 95% CI, 8.05-24.1) compared with nonbrain cancer (subdistribution HR, 1.60; 95% CI, 1.15-2.21) and without cancer (reference) (Table 4 and Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, in patients with active brain cancer, death due to bleeding continued to increase during follow-up, whereas rates of death due to VTE (fatal PE) were higher in the early phases after VTE diagnosis and then reached a plateau (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "At completing the multivariable risk analysis, patients with brain cancer and nonbrain cancer had a higher risk of recurrent VTE (subdistribution HR, 3.23; 95% CI, 2.13-4.86 and subdistribution HR, 2.97; 95% CI, 2.64-3.34, respectively) than patients without cancer (Table 4 and Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Rates of ICH, fatal ICH, and recurrent VTE were numerically (not significantly) higher in patients with glioblastoma than those with other malignant brain tumors (Table 5 and Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cumulative rates of ICH continued to increase during anticoagulation in patients with brain cancer (from 0.33% at 10 days to 3.16% at 90 days from the index VTE), whereas the increase was less pronounced in patients with nonbrain cancer or without cancer (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "At completing the risk analysis, brain cancer was the strongest predictor of ICH (subdistribution HR, 13.9; 95% CI, 8.05-24.1) compared with nonbrain cancer (subdistribution HR, 1.60; 95% CI, 1.15-2.21) and without cancer (reference) (Table 4 and Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, in patients with active brain cancer, death due to bleeding continued to increase during follow-up, whereas rates of death due to VTE (fatal PE) were higher in the early phases after VTE diagnosis and then reached a plateau (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "At completing the multivariable risk analysis, patients with brain cancer and nonbrain cancer had a higher risk of recurrent VTE (subdistribution HR, 3.23; 95% CI, 2.13-4.86 and subdistribution HR, 2.97; 95% CI, 2.64-3.34, respectively) than patients without cancer (Table 4 and Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Rates of ICH, fatal ICH, and recurrent VTE were numerically (not significantly) higher in patients with glioblastoma than those with other malignant brain tumors (Table 5 and Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cumulative rates of ICH continued to increase during anticoagulation in patients with brain cancer (from 0.33% at 10 days to 3.16% at 90 days from the index VTE), whereas the increase was less pronounced in patients with nonbrain cancer or without cancer (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "At completing the risk analysis, brain cancer was the strongest predictor of ICH (subdistribution HR, 13.9; 95% CI, 8.05-24.1) compared with nonbrain cancer (subdistribution HR, 1.60; 95% CI, 1.15-2.21) and without cancer (reference) (Table 4 and Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, in patients with active brain cancer, death due to bleeding continued to increase during follow-up, whereas rates of death due to VTE (fatal PE) were higher in the early phases after VTE diagnosis and then reached a plateau (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "At completing the multivariable risk analysis, patients with brain cancer and nonbrain cancer had a higher risk of recurrent VTE (subdistribution HR, 3.23; 95% CI, 2.13-4.86 and subdistribution HR, 2.97; 95% CI, 2.64-3.34, respectively) than patients without cancer (Table 4 and Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Rates of ICH, fatal ICH, and recurrent VTE were numerically (not significantly) higher in patients with glioblastoma than those with other malignant brain tumors (Table 5 and Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cumulative rates of ICH continued to increase during anticoagulation in patients with brain cancer (from 0.33% at 10 days to 3.16% at 90 days from the index VTE), whereas the increase was less pronounced in patients with nonbrain cancer or without cancer (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "At completing the risk analysis, brain cancer was the strongest predictor of ICH (subdistribution HR, 13.9; 95% CI, 8.05-24.1) compared with nonbrain cancer (subdistribution HR, 1.60; 95% CI, 1.15-2.21) and without cancer (reference) (Table 4 and Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, in patients with active brain cancer, death due to bleeding continued to increase during follow-up, whereas rates of death due to VTE (fatal PE) were higher in the early phases after VTE diagnosis and then reached a plateau (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "At completing the multivariable risk analysis, patients with brain cancer and nonbrain cancer had a higher risk of recurrent VTE (subdistribution HR, 3.23; 95% CI, 2.13-4.86 and subdistribution HR, 2.97; 95% CI, 2.64-3.34, respectively) than patients without cancer (Table 4 and Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Rates of ICH, fatal ICH, and recurrent VTE were numerically (not significantly) higher in patients with glioblastoma than those with other malignant brain tumors (Table 5 and Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cumulative rates of ICH continued to increase during anticoagulation in patients with brain cancer (from 0.33% at 10 days to 3.16% at 90 days from the index VTE), whereas the increase was less pronounced in patients with nonbrain cancer or without cancer (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "At completing the risk analysis, brain cancer was the strongest predictor of ICH (subdistribution HR, 13.9; 95% CI, 8.05-24.1) compared with nonbrain cancer (subdistribution HR, 1.60; 95% CI, 1.15-2.21) and without cancer (reference) (Table 4 and Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, in patients with active brain cancer, death due to bleeding continued to increase during follow-up, whereas rates of death due to VTE (fatal PE) were higher in the early phases after VTE diagnosis and then reached a plateau (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "At completing the multivariable risk analysis, patients with brain cancer and nonbrain cancer had a higher risk of recurrent VTE (subdistribution HR, 3.23; 95% CI, 2.13-4.86 and subdistribution HR, 2.97; 95% CI, 2.64-3.34, respectively) than patients without cancer (Table 4 and Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Rates of ICH, fatal ICH, and recurrent VTE were numerically (not significantly) higher in patients with glioblastoma than those with other malignant brain tumors (Table 5 and Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cumulative rates of ICH continued to increase during anticoagulation in patients with brain cancer (from 0.33% at 10 days to 3.16% at 90 days from the index VTE), whereas the increase was less pronounced in patients with nonbrain cancer or without cancer (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "At completing the risk analysis, brain cancer was the strongest predictor of ICH (subdistribution HR, 13.9; 95% CI, 8.05-24.1) compared with nonbrain cancer (subdistribution HR, 1.60; 95% CI, 1.15-2.21) and without cancer (reference) (Table 4 and Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, in patients with active brain cancer, death due to bleeding continued to increase during follow-up, whereas rates of death due to VTE (fatal PE) were higher in the early phases after VTE diagnosis and then reached a plateau (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "At completing the multivariable risk analysis, patients with brain cancer and nonbrain cancer had a higher risk of recurrent VTE (subdistribution HR, 3.23; 95% CI, 2.13-4.86 and subdistribution HR, 2.97; 95% CI, 2.64-3.34, respectively) than patients without cancer (Table 4 and Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Rates of ICH, fatal ICH, and recurrent VTE were numerically (not significantly) higher in patients with glioblastoma than those with other malignant brain tumors (Table 5 and Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cumulative rates of ICH continued to increase during anticoagulation in patients with brain cancer (from 0.33% at 10 days to 3.16% at 90 days from the index VTE), whereas the increase was less pronounced in patients with nonbrain cancer or without cancer (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "At completing the risk analysis, brain cancer was the strongest predictor of ICH (subdistribution HR, 13.9; 95% CI, 8.05-24.1) compared with nonbrain cancer (subdistribution HR, 1.60; 95% CI, 1.15-2.21) and without cancer (reference) (Table 4 and Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, in patients with active brain cancer, death due to bleeding continued to increase during follow-up, whereas rates of death due to VTE (fatal PE) were higher in the early phases after VTE diagnosis and then reached a plateau (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "At completing the multivariable risk analysis, patients with brain cancer and nonbrain cancer had a higher risk of recurrent VTE (subdistribution HR, 3.23; 95% CI, 2.13-4.86 and subdistribution HR, 2.97; 95% CI, 2.64-3.34, respectively) than patients without cancer (Table 4 and Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Cumulative rates of ICH continued to increase during anticoagulation in patients with brain cancer (from 0.33% at 10 days to 3.16% at 90 days from the index VTE), whereas the increase was less pronounced in patients with nonbrain cancer or without cancer (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "At completing the risk analysis, brain cancer was the strongest predictor of ICH (subdistribution HR, 13.9; 95% CI, 8.05-24.1) compared with nonbrain cancer (subdistribution HR, 1.60; 95% CI, 1.15-2.21) and without cancer (reference) (Table 4 and Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, in patients with active brain cancer, death due to bleeding continued to increase during follow-up, whereas rates of death due to VTE (fatal PE) were higher in the early phases after VTE diagnosis and then reached a plateau (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "At completing the multivariable risk analysis, patients with brain cancer and nonbrain cancer had a higher risk of recurrent VTE (subdistribution HR, 3.23; 95% CI, 2.13-4.86 and subdistribution HR, 2.97; 95% CI, 2.64-3.34, respectively) than patients without cancer (Table 4 and Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Rates of ICH, fatal ICH, and recurrent VTE were numerically (not significantly) higher in patients with glioblastoma than those with other malignant brain tumors (Table 5 and Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Rates of ICH, fatal ICH, and recurrent VTE were numerically (not significantly) higher in patients with glioblastoma than those with other malignant brain tumors (Table 5 and Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  }
]